IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Tybourne Capital Management HK LTD

Q3 2025 Holdings

Filed 2025-11-06 | 4 holdings | $30.9M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Taysha Gene Therapies Inc (Tsha US)(TSHA)COM SHS877619106$12.1M3,700,00039.1%
Forte Biosciences Inc (Fbrx US)(FBRX)COM NEW34962G208$11.8M786,64738.1%
Alumis Inc (Alms US)(ALMS)COM022307102$5.6M1,399,25018.0%
Zentalis Pharmaceuticals Inc (Zntl US)(ZNTL)COM98943L107$1.5M961,4864.7%